Venetoclax

TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS

Maintenance therapy in AML

Selection for time-limited & continuous therapy in CLL

The safety and efficacy of venetoclax-based treatment for patients with Richter’s syndrome

Key updates from the interim analysis of the FLAIR trial

Unmet needs in high-risk MDS and future therapeutic strategies

Updated PFS results of the GAIA/CLL13 trial

Venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13

Novel agents of interest for the treatment of BPDCN

Ponatinib + venetoclax for the treatment of R/R Ph+ALL

Fixed-duration vs continuous therapy in CLL

Oral combination of HMAs + venetoclax in unfit or elderly patients with AML

Working towards a cure in CML

Ongoing trials in AML and HR-MDS: ENHANCE, ENHANCE-2 and ENHANCE-3

Safety & efficacy of nelarabine, pegylated asparaginase and venetoclax in frontline therapy of T-ALL

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL